CAMP4 Therapeutics (CAMP) vs Keros Therapeutics (KROS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
CAMP4 Therapeutics (CAMP) has outperformed Keros Therapeutics (KROS) over the past year, losing 0.5% versus a loss of 25.9%. Keros Therapeutics is the larger company by market cap ($236.9 million vs $236.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAMP | KROS |
|---|---|---|
| Share price | $3.77 | $11.95 |
| Market cap | $236.58M | $236.93M |
| 1-day change | +1.89% | +2.66% |
| YTD return | -38.50% | -41.31% |
| 1-year return | -0.53% | -25.87% |
| 5-year return | — | -69.35% |
| EPS (TTM) | $-2.32 | $-3.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $22.55 |
| 52-week low | $2.86 | $9.69 |
| Distance from 52-week high | -51.35% | -47.01% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +180.37% | +65.94% |
| Average volume | 278.11K | 194.05K |
| Shares outstanding | 62.75M | 19.83M |
| Employees | 48 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAMP has outperformed KROS by 25.3 percentage points over the past year.
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
CAMP vs KROS FAQ
Which is bigger, CAMP4 Therapeutics or Keros Therapeutics?
Keros Therapeutics (KROS) is larger, with a market capitalization of $236.93M compared with $236.58M for CAMP4 Therapeutics (CAMP).
Which stock has performed better over the past year, CAMP or KROS?
CAMP returned -0.53% over the past 12 months, compared with -25.87% for KROS (price return, excluding dividends). Past performance does not predict future results.
Are CAMP4 Therapeutics and Keros Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.